Biotechnology company Tubulis has announced it has raised a record $361 million in financing to expand its clinical development of the antibody-drug conjugate (ADC) candidate TUB-040. The financing represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally. The financing round was led by Venrock […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!